CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO.,LTD.

CCSB has developed more than 30 bulk pharmaceutical products including Anti-Anxiety agent, Antidiabetics, Laxatives, Antifungals, Cardiovascular drugs, Skeletal, Muscle relaxants, Hypolipaemics, Antineoplastic, Antihyperlipedemia, Immunosuppresant and peptide drugs. In 1984, CCSB was the first pharmaceutical manufacturer in Taiwan inspected and approved by FDA for cGMP compliance. CCSB has filed DMF's for 29 products with the FDA.        

CCSB has established a sales office, in 1999 Pharmaports LLC in Exton, PA USA to promote its products and provide better services to the North American region. Together, the group has formed an international network providing pharmaceutical ingredients and finished dosages.

In November 2022, CCSB passed again the FDA inspection of our cGMP plant to produce synthesis and biotechnology products.

CCSB granted the GMP certification in Baricitinib, Caspofungin Acetate, Ethyl Icosapentate, Everolimus, Everolimus B02, Everolimus B20, Everolimus Pre-Mix, Favipiravir, Fluconazole, Guaifenesin, Ixazomib Citrate, Methocarbamol, Mycophenolate Mofetil, Mycophenolate Mofetil Hydrochloride Anhydrous, Mycophenolate Sodium, Palbociclib, Pravastatin Sodium, Rapamycin, Sugammadex Sodium, Tacrolimus and Trandolapril  from Taiwan FDA, a member of PIC/S.

CCSB will continuously pursue the goal of quality products and quality service through our expert and experienced team to become a worldwide major supplier of high-quality APIs with outstanding international regulatory compliance policies.